Peptide comparator
Set two or three peptides next to each other: FDA status, the goals each is looked up for, the evidence behind each goal, the forms sellers price and the largest human study.
Compared onSemaglutideTirzepatide
Status
SemaglutideFDA-approved
TirzepatideFDA-approved
What the status rests on
SemaglutideWegovy (semaglutide) injection, NDA 215256, approved for chronic weight management. Source
TirzepatideZepbound (tirzepatide) injection, NDA 217806, approved for chronic weight management. Source
Looked up for, and the evidence
Semaglutide
- Weight: Large trials
Tirzepatide
- Weight: Large trials
Forms sellers price
SemaglutideInjection, Oral, Sublingual
TirzepatideInjection, Oral, Sublingual, Topical
Dose steps up on a schedule
SemaglutideYes, in steps
TirzepatideYes, in steps
Human studies we cite
Semaglutide3
Tirzepatide2
Largest of them
SemaglutideLincoff 2023: randomized trial of 17,604 people
TirzepatideJastreboff 2022: randomized trial of 2,539 people
Sellers we have reviewed
Semaglutide11
Tirzepatide10
Frequently asked questions
- What does each evidence label mean?
- Large trials means at least one randomized trial of 1,000 or more people measured the goal. Mid-size trials means the largest had at least 100. Small studies, early human data and lab and animal only step down from there.
- Why do MOTS-c, BPC-157, Kisspeptin show no guide and no sellers?
- They have no lawful pharmacy route today, so this site writes no buying guide and lists no seller for them. Their status line says which list they are on, or that they are on none.
- Where do the forms come from?
- From the prices on our roster. A form appears only where a seller we track publishes a price for it and a pharmacy may lawfully make it in that form: GHK-Cu, for example, may be compounded as a cream or a spray but not as an injection.
For two sellers side by side rather than two peptides, see the comparisons.